Patent US4803221A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4803221A Expired / Lapsed US ⏱️ 0.0 years remaining

Anthracene derivatives

Assignee: SmithKline Beecham Corp
•
Filing: 1987-08-28
•
Granted: 1989-02-07
•
Expires: 2007-08-28
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is an anthracene or substituted anthracene ring system; R 1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R 5 is hydrogen; R 6 and R 7 are the same or different and each is hydrogen or C 1-3 alkyl optionally substituted by hydroxy; R 8 and R 9 are the same or different and each is hydrogen or C 1-3 alkyl; ##STR2## is a five- or six-membered saturated carbocyclic ring; R 10 is hydrogen, methyl or hydroxymethyl; R 11 , R 12 and R 13 are the same or different and each is hydrogen or methyl; R 14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

Inventors

  • 👤 Kenneth W. Bair

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-01 03:12
CPC Classifications
A; A61; A61K; A61K8/00; A61K8/18; A61K8/72; A61K8/81; A61K8/8105; A61K8/8117; A61K8/8141; A61K8/8147; A61K8/8158; A61K8/8164; A61K8/817; A61K8/8182; A61K8/8194; A61K8/84; A61K8/88; A61Q; A61Q5/00; A61Q5/02; A61Q5/04; A61Q5/06; A61Q5/10; A61Q9/00; A61Q9/02; D; D06; D06M; D06M15/00; D06M15/19; D06M15/21; D06M15/263; D06M15/267; D06M15/285; D06M15/356; A61K2800/00; A61K2800/40; A61K2800/54; A61K2800/542; A61K2800/5424; A61K2800/5426; A61K2800/59; A61K2800/594

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 310 words
A pharmaceutical formulation containing a compound of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or monoethyl ether thereof, the compound of formula (I) including its ethers containing no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is an anthracene ring optionally substituted by one or two substituents. The substituents will contain not more than four carbon atoms in total when taken together being the same or different and are selected from halogen; cyano; C 1-4 alkyl or C 1-4 alkoxy, each optionally substituted by hydroxy or C 1-2 alkoxy; halogen substituted C 1-2 alkyl or C 1-2 alkoxy; a group S(O) n R 2 wherein n is an integer 0, 1 or 2 and R 2 is C 1-2 alkyl optionally substituted by hydroxy or C 1-2 alkoxy; or the anthracene ring is optionally substituted by a group NR 3 R 4 containing not more than 5 carbon atoms wherein R 3 and R 4 are the same or different and each is a C 1-3 alkyl group; R 1 contains not more than eight carbon atoms and is a group ##STR11## wherein m is 0 or 1; R 5 is hydrogen; R 6 and R 7 are the same or different and each is hydrogen or C 1-3 alkyl optionally substituted by hydroxy (proving that at least one hydroxy group is present); R 8 and R 9 are the same or different and each is hydrogen or C 1-3 alkyl; ##STR12## is a five- or six-membered saturated carbocyclic ring; R 10 is hydrogen, methyl or hydroxymethyl; R 11 , R 12 and R 13 are the same or different and each is hydrogen or methyl; R 14 is hydrogen, methyl, hydroxy, or hydroxymethyl, except 2-((10-(2-hydroxyethyloxy)-9-anthracenylmethyl)amino-2-methyl-1,3-propanediol with a pharmaceutically acceptable carrier in the form of a tablet, capsule, syrup, or solution.
Claim 2
Dependent Claim 310 words
A pharmaceutical formulation containing a compound of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or monoethyl ether thereof, the compound of formula (I) including its ethers containing no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is an anthracene ring optionally substituted by one or two substituents. The substituents will contain not more than four carbon atoms in total when taken together being the same or different and are selected from halogen; cyano; C 1-4 alkyl or C 1-4 alkoxy, each optionally substituted by hydroxy or C 1-2 alkoxy; halogen substituted C 1-2 alkyl or C 1-2 alkoxy; a group S(O) n R 2 wherein n is an integer 0, 1 or 2 and R 2 is C 1-2 alkyl optionally substituted by hydroxy or C 1-2 alkoxy; or the anthracene ring is optionally substituted by a group NR 3 R 4 containing not more than 5 carbon atoms wherein R 3 and R 4 are the same or different and each is a C 1-3 alkyl group; R 1 contains not more than eight carbon atoms and is a group ##STR11## wherein m is 0 or 1; R 5 is hydrogen; R 6 and R 7 are the same or different and each is hydrogen or C 1-3 alkyl optionally substituted by hydroxy (proving that at least one hydroxy group is present); R 8 and R 9 are the same or different and each is hydrogen or C 1-3 alkyl; ##STR12## is a five- or six-membered saturated carbocyclic ring; R 10 is hydrogen, methyl or hydroxymethyl; R 11 , R 12 and R 13 are the same or different and each is hydrogen or methyl; R 14 is hydrogen, methyl, hydroxy, or hydroxymethyl, except 2-((10-(2-hydroxyethyloxy)-9-anthracenylmethyl)amino-2-methyl-1,3-propanediol with a pharmaceutically acceptable carrier in the form of a tablet, capsule, syrup, or solution.
Claim 3
Dependent Claim 76 words
A method of claim 1 for a compound of formula (I) wherein Ar is 9-anthracenyl, ##STR13## R 1 is ##STR14## wherein m is 0; R 16 is CH 2 OH, CH(CH 3 )OH or CH 2 CH 2 OH; R 17 is hydrogen, C 1-3 alkyl or CH 2 OH; R 18 is hydrogen or methyl; or a monomethyl or monoethyl ether thereof containing no more than 28 carbon atoms in total; acid addition salts thereof.
Claim 4
Dependent Claim 31 words
A method of claim 2 wherein R 16 is CH 2 OH or CH(CH 3 )OH and R 17 is hydrogen, methyl, ethyl or CH 2 OH; acid addition salts thereof.
Claim 5
Dependent Claim 34 words
A method of claim 3 wherein R 1 is a diol of the structure ##STR15## wherein R 19 is hydrogen or methyl and R 20 is hydrogen, methyl or ethyl; acid addition salts thereof.
Claim 6
Dependent Claim 14 words
A method of claim 4 wherein R 20 is methyl; acid addition salts thereof.
Claim 7
Dependent Claim 23 words
A method of claim 1 wherein the compound of formula (I) is a methane-sulfonic, hydrochloric, ethanesulfonic, lactic, citric or isethionic acid addition salt.
Claim 8
Dependent Claim 66 words
A method of claim 1 wherein a compound of formula (I) is selected from 2-(((10-Chloro-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-((9-Anthracenylmethyl)amino)-2-methyl-1,3-propanediol, 2-Methyl-2-(((10-methylthio-9-anthracenyl)methyl)amino)-1,3-propanediol, 2-(((10-(2-Chloroethyl)-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((4,10-Dichloro-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((10-Hydroxymethyl-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-Methyl-2-(((10-methyl-9-anthracenyl)methyl)amino)-1,3-propanediol, 2-(((10-Bromo-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((10-Chloro-9-anthracenyl)methyl)amino)-2-ethyl-1,3-propanediol, 2-(((4,5-Dichloro-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((4-Chloro-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-Methyl-2-(((10-methylsulfinyl-9-anthracenyl)methyl)amino)-1,3-propanediol 2-(((10-Methoxy-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 10-((1,1-Bis(hydroxymethyl)ethylamino)methyl)-9-anthracenecarbonitrile, 2-(((10-Bromo-1-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-((1-Anthracenylmethyl)amino)-2-methyl-1,3-propanediol, 2-(((2-Chloro-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((10-Ethylthio-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((10-(2-Hydroxyethylthio)-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((10-Chloro-9-anthracenyl)methyl)amino)-2-hydroxymethyl-1,3-propanediol, 2-(((3,10-Dichloro-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((2,10-Dichloro-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((10-Ethoxy-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-Methyl-2-(((10-methylsulfonyl-9-anthracenyl)methyl)amino)-1,3-propanediol 2-(((3-Chloro-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((2-Ethyl-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol and 2-(((3-Ethyl-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, (+-)(2R*,3S*)-2-((9-Anthracenylmethyl)amino)-2-methyl-1,3-butanediol, 2-((9-Anthracenylmethyl)amino)-2-ethoxymethyl-1,3-propanediol, 2-(((10-Chloro-1-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((10-(2-Methoxyethoxy)-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-Methyl-2-(((10-N-morpholino-9-anthracenyl)methyl)amino)-1,3-propanediol, 2-((9-Anthracenylmethyl)amino)-3-methoxy-2-methyl-1-propanol, 2-((9-Anthracenylmethyl)amino)-2-isopropyl-1,3-propanediol, 2-((9-Anthracenylmethyl)amino)-2-methyl-1,4-butanediol, 2-(((10-(1H-Imidazol-1-yl)-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, (1α,2β,3α)-2-((9-Anthracenylmethyl)amino)-1,3-cyclohexanediol, 2-(((4-Chloro-10-(2-hydroxyethoxy)-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-Methyl-2-(((4,5,10-trichloro-9-anthracenyl)methyl)amino)-1,3-propanediol, 2-(((10-Chloro-2,3-dimethyl-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((2-tert-Butyl-10-chloro-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-(((3-tert-Butyl-10-chloro-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol, 2-((2-Anthracenylmethyl)amino)-2-methyl-1,3-propanediol, 2-Methyl-2-((2,6,10-trichloro-9-anthracenyl)methyl)amino)1,3-propanediol, 2-(((10-Butoxy-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol and 2-(((10-Butyl-9-anthracenyl)methyl)amino)-2-methyl-1,3-propanediol; acid addition salts thereof.
Claim 9
Dependent Claim 23 words
A method of claim 7 wherein the compound of formula (I) is a methane-sulfonic, hydrochloric, ethanesulfonic, lactic, citric or isethionic acid addition salt.
Claim 10
Dependent Claim 14 words
A pharmaceutical formulation of claim 1 in the form of a solution for injection.
Claim 11
Dependent Claim 14 words
A pharmaceutical formulation of claim 2 in the form of a solution for injection.
Claim 12
Dependent Claim 33 words
The method of reducing the cells of a susceptible tumor which comprises contacting said susceptible tumor cells with a tumor reducing amount of the compound or salt of the formulation of claim 1.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-02-07 1992-08-08 1993-02-07 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-02-07 1996-08-08 1997-02-07 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-02-07 2000-08-08 2001-02-07 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag